The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 31, 2022
Filed:
Jul. 27, 2017
Applicant:
Case Western Reserve University, Cleveland, OH (US);
Inventors:
Paul Tesar, Wickliffe, OH (US);
Drew Adams, Cleveland, OH (US);
Zita Hubler, Cleveland, OH (US);
Matthew Elitt, Shaker Heights, OH (US);
Dharmaraja Allimuthu, Cleveland, OH (US);
Steven B. Landau, Wellesley, MA (US);
Assignee:
Case Western Reserve University, Cleveland, OH (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/137 (2006.01); A61P 25/28 (2006.01); A61K 45/06 (2006.01); A61K 31/198 (2006.01); A61K 39/395 (2006.01); A61K 38/16 (2006.01); A61K 31/136 (2006.01); A61K 38/21 (2006.01); A61P 25/14 (2006.01); A61K 31/4545 (2006.01); A61K 31/7105 (2006.01); A61K 31/496 (2006.01); A61K 31/4174 (2006.01); A61K 31/138 (2006.01); A61K 31/5375 (2006.01); A61K 31/4196 (2006.01); A61K 31/4535 (2006.01); C12N 9/50 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
A61K 31/137 (2013.01); A61K 31/136 (2013.01); A61K 31/138 (2013.01); A61K 31/198 (2013.01); A61K 31/4174 (2013.01); A61K 31/4196 (2013.01); A61K 31/4535 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/5375 (2013.01); A61K 31/7105 (2013.01); A61K 38/16 (2013.01); A61K 38/215 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 25/14 (2018.01); A61P 25/28 (2018.01); C12N 9/50 (2013.01); C12N 15/1137 (2013.01);
Abstract
A method of promoting the generation of oligodendrocytes from oligodendrocyte precursor cells by enhancing their survival and/or maturation includes administering to the cell an effective amount of an agent that enhances and/or induces accumulation of Δ8,9-unsaturated sterol intermediates of the cholesterol biosynthesis pathway in the oligodendrocyte precursor cells.